- Open
- 0.18
- High
- 0.17
- Low
- 0.17
- Close
- 0.17
- Change
- -0.01 (-5.56%)
- Volume
- 683,938
| 2 Oct 2026 | 07:00:03 | Australian partner to progress Ox-1 Phase 1 trial |
| 30 Sept 2026 | 07:00:08 | Posting of Annual Report and Notice of AGM |
| 28 Sept 2026 | 07:00:07 | Final Results for the year ended 31 March 2026 |
| 14 Sept 2026 | 07:00:11 | Notice of Results and Investor Presentation |
| 29 Aug 2025 | Annual Report and Accounts (to 2025-03-31) | |
| 15 Jul 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 21 Sep 2023 | Annual Report and Accounts (to 2023-03-31) |
TheraCryf PLC develops therapeutics for brain disorders, focusing on neuropsychiatry, particularly addiction and fatigue. Its lead program is an orexin-1 antagonist targeting binge eating disorder, while a second program involves a dopamine transporter antagonist aimed at fatigue related to conditions like multiple sclerosis. The company also collaborates with Erasmus Medical Centre on a grant-funded project for SFX-01, a treatment for glioblastoma. TheraCryf operates as a virtual biotech, outsourcing research and development while aiming to license its drug candidates to larger pharmaceutical companies after reaching proof-of-concept trials.
| 2 Oct 2026 | 07:00:03 | Australian partner to progress Ox-1 Phase 1 trial |
| 30 Sept 2026 | 07:00:08 | Posting of Annual Report and Notice of AGM |
| 28 Sept 2026 | 07:00:07 | Final Results for the year ended 31 March 2026 |
| 14 Sept 2026 | 07:00:11 | Notice of Results and Investor Presentation |
| 29 Aug 2025 | Annual Report and Accounts (to 2025-03-31) | |
| 15 Jul 2024 | Annual Report and Accounts (to 2024-03-31) | |
| 21 Sep 2023 | Annual Report and Accounts (to 2023-03-31) |
TheraCryf PLC develops therapeutics for brain disorders, focusing on neuropsychiatry, particularly addiction and fatigue. Its lead program is an orexin-1 antagonist targeting binge eating disorder, while a second program involves a dopamine transporter antagonist aimed at fatigue related to conditions like multiple sclerosis. The company also collaborates with Erasmus Medical Centre on a grant-funded project for SFX-01, a treatment for glioblastoma. TheraCryf operates as a virtual biotech, outsourcing research and development while aiming to license its drug candidates to larger pharmaceutical companies after reaching proof-of-concept trials.
| 11 Sept 2026 | 15:52:31 | Holding(s) in Company |
| 14 Apr 2026 |
| AIM movers: James Cropper profit recovery and TheraCryf turns down approach for main asset |
| 11 Sept 2026 | 15:52:31 | Holding(s) in Company |
| 14 Apr 2026 |
| AIM movers: James Cropper profit recovery and TheraCryf turns down approach for main asset |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £311m | +0.2% | |
| £29m | — | |
| £8m | -0.7% | |
| £1m | -0.7% | |
TCFTheracryf PLC | £741k | -0.2% |
| £342k | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £311m | +0.2% | |
| £29m | — | |
| £8m | -0.7% | |
| £1m | -0.7% | |
TCFTheracryf PLC | £741k | -0.2% |
| £342k | -0.8% |